VCYT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Veracyte

Veracyte shares opened down approximately $23.25, or 44.27%, to about $29.27 on November 5 after the company reported Decipher Prostate volume below expectations. Q3 revenue was $151.8 million and Veracyte authorized a $100 million buyback, but it narrowed 2026 revenue guidance to $590 million–$593 million from $590 million–$596 million; the new upper end is below the cited $593.894 million analyst estimate. The company reportedly expects Decipher test volume to increase by 12,000–15,000, versus the CEO's prior projection of an average 20,000 annual increase; a law firm announced an investigation into potential securities-law violations concerning statements about Decipher's growth outlook.

Analysis

The core repricing is likely about Decipher’s growth durability, not the quarter’s headline revenue: if test growth is structurally lower, investors may reduce the multiple applied to the franchise before the revenue shortfall becomes large in reported results. Afirma strength may cushion near-term consolidated growth, but does not establish that it can replace Decipher’s growth contribution. A potential beneficiary is Myriad Genetics’ Prolaris through clinician or payer substitution, although share gains are unproven and should be checked against utilization data.

The buyback is not a demand catalyst by itself: authorization is not execution, and without cash-flow and balance-sheet detail it cannot be treated as a durable valuation floor. The securities investigation is a secondary overhang; the press release is investor-solicitation material, not evidence of liability. Near term, litigation headlines may add volatility, while the 1–3 month catalyst is management’s explanation of the volume miss and updated test-growth trajectory. Over 6–18 months, the key question is whether lower Decipher growth persists or reflects timing/channel noise.

Contrarian angle: after a reported one-day gap down, an immediate short risks fading an already severe reset; the market may have priced in a lasting deterioration before that is verified. Conversely, the buyback headline should not be read as proof management sees the shares as undervalued. Verify actual trading data, test volumes, reimbursement/channel trends, cash generation, and buyback execution before sizing.

Key Decisions for Investors

• Avoid chasing VCYT short at the open after the reported gap. Put it on a 1–3 month event watchlist; consider a small, defined-risk bearish position only if management confirms the lower Decipher growth path and subsequent volume data fail to recover. Reassess if test growth reaccelerates or guidance is restored.
• Do not underwrite the buyback as a floor until filings show repurchases are occurring and cash generation supports them. Track Decipher test volume and growth commentary separately from Afirma results; consolidated revenue alone could obscure continued weakness in the key growth driver.
• Check Myriad Genetics’ Prolaris utilization, payer coverage, and clinician adoption for evidence of substitution before expressing a relative-value trade. No competitor long is warranted on this report alone.
• Treat the securities investigation as headline risk, not a fundamental signal. Revisit only if a formal complaint, materially adverse disclosure, or management clarification changes the expected cost or duration of the overhang.